Dare Bioscience Inc expected to post a loss of 24 cents a share - Earnings Preview

Dare Bioscience

11/08/2026 22:04

Dare Bioscience Inc DARE.OQ DARE.O is expected to  show a rise in quarterly revenue when it reports  results on August 13 for the period ending June 30 2026

​LSEG's mean analyst estimate for Dare Bioscience Inc is for a loss of 24 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Dare Bioscience Inc is $9.00, about 561.8% above its last closing price of $1.36
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.31
-0.29
-0.20
Beat
31
Dec. 31 2026
-0.43
-0.02
Beat
95.4
Sep. 30 2025
-0.36
-0.36
-0.28
Beat
21.5​
Jun. 30 2025
-0.60
-0.58
-0.45
Beat
22.4
​​Mar. 31 2025
-0.58
-0.58
-0.50
Beat
13.8
Dec. 31 2024
-0.53
-0.65
Missed
-21.9​
Sep. 30 2024
-0.76
-0.73
-0.55
Beat
25
Jun. 30 2024
-0.65
0.00
1.52
Beat
This summary was machine generated August 11 at 21:04 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)